CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate CVnCoV

CureVac NV (Nasdaq: CVAC), a biopharmaceutical company developing a new class of drugs based on messenger ribonucleic acid (mRNA) in clinical trials, today announced data from preclinical studies of its SARS-CoV-2 vaccine candidate CVnCoV in mice and hamsters . The vaccine candidate triggers a balanced humoral and cellular immune response, which is characterized by high antibody titers and very good T-cell activation. In addition to the positive immune response, the vaccine candidate was able to elicit favorable Th1 cytokine levels.